Reps. Arvind Venkat and Bryan Cutler are set to propose a new bill in Pennsylvania aimed at ensuring the availability of GLP-1 medications for Medicaid patients while reducing state costs. The proposed legislation introduces a “subscription model” that allows the state to purchase these drugs at a lower cost by paying a fixed amount per treatment up to a certain limit, after which additional treatments would be provided by the manufacturer at no extra charge.
Venkat emphasized the health benefits of GLP-1 medications, stating they can prevent serious diseases such as type 2 diabetes and cardiovascular disease. “For the state, healthier outcomes for Medicaid patients translate to significant cost savings,” he noted. The challenge lies in the current high costs of these medications versus future savings from reduced disease rates.
The subscription model, also referred to as the “Netflix model,” offers states an opportunity to negotiate better prices through bulk purchasing, providing greater certainty in pharmaceutical expenses. Drug companies have shown interest due to the large-scale nature of purchases under this system.
Cutler highlighted the importance of this legislation for Pennsylvanians needing obesity medication and expressed gratitude towards Venkat for his collaboration on this initiative. Both lawmakers cited successful implementations of similar models in Louisiana and Washington for Hepatitis C treatments, with significant reductions in medication costs reported.
Venkat stressed the need for Pennsylvania to ensure ongoing access to GLP-1 medications amidst rising demand and evidence of their efficacy. He believes that adopting a subscription model could achieve this goal while saving millions in prescription costs. Efforts are underway to gather co-sponsors, with plans to introduce the bill later this week.
